P95 Julius Clinical

Global CRO managing complex clinical trials

P95 Julius Clinical

Global CRO managing complex clinical trials

Overview

Julius Clinical is a full-service contract research organization that manages complex global clinical trials for pharmaceutical, biotech, government, and academic clients from start to finish. It provides end-to-end development services—study design, project management, patient and site recruitment, data management, and biostatistics—across all trial phases. Its strength comes from its academic heritage (originating at the Julius Center, Utrecht) and a worldwide network of KOLs and sites, with focus in CNS, cardio-metabolic, infectious, renal, and rare diseases, plus growth via partnerships such as Ampersand’s investment and the Peachtree BioResearch Solutions merger. The goal is to deliver scientifically solid, efficient trials that meaningfully impact medical practice while expanding its global footprint and depth of expertise.

Significant Headcount Growth

Work here?Claim your company

About P95 Julius Clinical

Simplify's Rating

Not yet rated

We're working on gathering enough insights on this company, check back soon!

Industries

Data & AnalyticsConsultingHealthcare

Company Size

201-500

Company Stage

N/A

Total Funding

N/A

Headquarters

Zeist, Netherlands

Founded

2008

Get referred to P95 Julius Clinical

See people who can refer or advise you

Benefits

Remote Work Options

Growth & Insights and Company News

6 month growth

14%

1 year growth

2 year growth

GlobeNewswire

Nov 19th, 2025

P95 and Julius Clinical Merge Globally

P95 and Julius Clinical have merged to form a global clinical research organization specializing in neuroscience, cardio-renal-metabolic, and infectious diseases and vaccines. The new entity, led by CEO Bassem Saleh, comprises over 500 professionals in 25+ countries, delivering clinical development and real-world evidence programs across five continents. The merger combines Julius Clinical's trial expertise with P95's epidemiology and RWE leadership.

PR Newswire

May 14th, 2025

Julius Clinical And Peachtree Bioresearch Solutions Merge To Form A Fully Integrated Global Cro With Increased Cns Capabilities

ZEIST, Netherlands, May 14, 2025 /PRNewswire/ -- Julius Clinical, a leading full-service Contract Research Organization (CRO) headquartered in the Netherlands (Zeist), and Peachtree BioResearch Solutions, a specialized CNS CRO based in the United States (Georgia), announce they have merged as a fully integrated clinical research organization. The merger combines scientific and operational excellence, an expanded international footprint and increased capabilities across therapeutic areas, particularly within CNS. Building on nearly a decade of successful collaboration between the two companies, the merged organization creates a comprehensive clinical CRO, bringing together extensive expertise in managing Phase I - III clinical trials with particular depth in central nervous system (CNS), cardio-metabolic, renal and rare diseases. Their combined strength delivers end-to-end clinical research services, enhanced global access in Europe and North America, and robust scientific expertise tailored to pharmaceutical-, biotech-, and medical device companies

PR Newswire

Feb 25th, 2025

Julius Clinical Strengthens Its European Capabilities By Expanding Operations In Poland

ZEIST, Netherlands, Feb. 25, 2025 /PRNewswire/ -- Julius Clinical, a science-driven global CRO specializing in Neurological, Cardio-Metabolic, Renal and Rare Diseases, is pleased to announce the establishment of Julius Clinical Poland, a new operational hub in Krakow. This expansion reinforces Julius Clinical's position as a global leader in CNS and Cardio-Metabolic research while enhancing its pan-European capabilities in clinical trials.With a strong track record of over 15 clinical trials conducted in Poland during the last years, Julius Clinical recognizes the country's exceptional potential as a key clinical research hub in Europe. Poland offers a highly skilled workforce, a robust healthcare infrastructure, and a proven commitment to clinical research, making it an optimal destination for expanding the company's European footprint. The new affiliate will enable more efficient patient recruitment, improved site selection, and seamless regulatory compliance, ultimately accelerating the development of innovative therapies.Martijn Wallert, CEO of Julius Clinical, said: "Expanding into Poland marks a strategic milestone for Julius Clinical. We are strengthening our presence in Eastern Europe, making Poland a central hub for our regional operations and expanding our ability to support clinical research across neighboring countries."Radek Korba, Country Manager Poland, brings long-standing collaboration experience with Julius Clinical, ensuring a smooth transition for customers and partners

ACN Newswire

May 31st, 2024

Avance Clinical Expands Specialist Cns, Cardiometabolic, And Rare Diseases Cro Services In Europe With Julius Clinical

WAKE FOREST, N.C. | ADELAIDE, AUS, May 31, 2024 - (ACN Newswire) - Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs has signed a Memorandum of Understanding (MOU) with Julius Clinical, a leading CNS, cardiometabolic, and rare diseases specialist CRO with extensive site relationships in the region. Meet the Avance Clinical team at BIO 2024 – Book a meeting now. Julius Clinical, established in 2008 and headquartered in Zeist, The Netherlands, specializes in CNS, cardiometabolic, and rare diseases. The non-exclusive MOU between Avance Clinical and Julius Clinical offers a streamlined global solution for biotech clients

Recently Posted Jobs